Saniona progresses its Kv7 epilepsy program into Lead
PRESS RELEASE August 16, 2022 Saniona (OMX: SANION), a clinical stage biopharmaceutical company, today announced that it has progressed its promising Kv7...
Thomas Feldthus Palle Christophersen Lead Optimization Phase Nasdaq Stockholm Small Cap Stockholm Stock Exchange Sanion Saniona Ab
Source: globenewswire.com